Axonics, Inc. (NASDAQ:AXNX) Shares Bought by Algert Global LLC

Algert Global LLC increased its position in Axonics, Inc. (NASDAQ:AXNX) by 117.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 73,627 shares of the company’s stock after buying an additional 39,780 shares during the quarter. Algert Global LLC owned about 0.14% of Axonics worth $5,124,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of AXNX. Headlands Technologies LLC lifted its holdings in Axonics by 162.1% in the 2nd quarter. Headlands Technologies LLC now owns 2,928 shares of the company’s stock valued at $197,000 after acquiring an additional 1,811 shares during the last quarter. Xponance Inc. lifted its stake in Axonics by 7.5% during the second quarter. Xponance Inc. now owns 3,231 shares of the company’s stock valued at $217,000 after purchasing an additional 225 shares during the last quarter. Entropy Technologies LP bought a new stake in Axonics during the third quarter worth approximately $395,000. Mercer Global Advisors Inc. ADV lifted its position in shares of Axonics by 12.7% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 6,981 shares of the company’s stock valued at $469,000 after acquiring an additional 785 shares during the last quarter. Finally, SG Americas Securities LLC boosted its stake in shares of Axonics by 379.6% during the 2nd quarter. SG Americas Securities LLC now owns 8,321 shares of the company’s stock worth $559,000 after acquiring an additional 6,586 shares in the last quarter. Institutional investors own 99.48% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reissued a “hold” rating on shares of Axonics in a research report on Friday, November 8th. Eight equities research analysts have rated the stock with a hold rating, According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $71.00.

Axonics Stock Up 0.8 %

Shares of NASDAQ AXNX opened at $70.98 on Monday. Axonics, Inc. has a 12 month low of $55.09 and a 12 month high of $71.05. The company has a market cap of $3.63 billion, a P/E ratio of -591.45 and a beta of 0.82. The business’s 50 day moving average is $70.09 and its two-hundred day moving average is $68.73.

Insider Activity at Axonics

In other news, CFO Kari Leigh Keese sold 2,961 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $69.41, for a total transaction of $205,523.01. Following the completion of the transaction, the chief financial officer now owns 40,362 shares of the company’s stock, valued at approximately $2,801,526.42. This represents a 6.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.85% of the company’s stock.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.